Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. EQT AB (publ)
  6. News
  7. Summary
    EQT   SE0012853455

EQT AB (PUBL)

(EQT)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/19 06:22:35 am
400.65 SEK   -3.32%
01:49aEQT Invested EUR20.6 Billion in 2021; Assets Under Management Rose 40%
DJ
01:24aEQT FY21 Profit Nearly Triples as Management Fees Drive Revenue
MT
01:01aEQT AB (publ) Year-end Report 2021
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sweden's Karo Pharma to buy Sylphar in $326 million deal

11/23/2021 | 02:19am EST

STOCKHOLM (Reuters) - Specialty pharma group Karo Pharma has agreed to buy Belgium-based Sylphar International from Vendis Capital and Sylphar's founder for 290 million euros ($326 million), it said on Tuesday.

Karo Pharma said Sylphar, which develops and markets over-the-counter products, would boost its market position and help it grow, particularly in the digital marketplace.

The Swedish company added that it would carry out a new share issue of around 200 million to 250 million euros, with preferential rights for its existing shareholders.

Karo Intressenter AB, owned by private equity firm EQT and which has a 79.85% stake in Karo Pharma, is supporting the transaction, it said.

"Karo estimates that the transaction brings synergy potential for the company, predominantly in the form of sales synergies," Karo Pharma said in a statement.

Sylphar, whose main brands are Nutravita, Alpha Foods andRemescar, had sales of around 64 million euros in the October-September period.

Karo Pharma said an additional payment of 10 million eurosmay be paid if certain growth targets for Sylphar are met, adding the transaction would be completed in January 2022.

($1 = 0.8901 euros)

(Reporting by Helena Soderpalm; editing by Niklas Pollard)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
EQT AB (PUBL) -3.40% 400.4 Delayed Quote.-15.94%
KARO PHARMA AB (PUBL) -0.35% 57.6 Delayed Quote.-3.67%
All news about EQT AB (PUBL)
01:49aEQT Invested EUR20.6 Billion in 2021; Assets Under Management Rose 40%
DJ
01:24aEQT FY21 Profit Nearly Triples as Management Fees Drive Revenue
MT
01:01aEQT AB (publ) Year-end Report 2021
AQ
12:40aEMEA MORNING BRIEFING : Shares to Tumble Again as -2-
DJ
12:16aNEWS HIGHLIGHTS : Top Financial Services News of the Day
DJ
01/18EQT Aims for $22.7 Billion Fund Size for EQT X
MT
01/18EQT sets target fund size of EQT X at EUR 20ábillion
AQ
01/17EQT AB : Zorro Bidco holds a total of 97 percent in zooplus after completion of the public..
EQ
01/05Invitation to presentation of EQT AB's Year-end Report 2021
AQ
2021EUROPEAN MIDDAY BRIEFING - Shares Little Changed, Appetite Remains Fragile
DJ
More news
Analyst Recommendations on EQT AB (PUBL)
More recommendations
Financials
Sales 2021 1 461 M 1 657 M 1 657 M
Net income 2021 796 M 903 M 903 M
Net cash 2021 628 M 712 M 712 M
P/E ratio 2021 49,7x
Yield 2021 0,95%
Capitalization 39 519 M 44 831 M 44 824 M
EV / Sales 2021 26,6x
EV / Sales 2022 22,6x
Nbr of Employees 938
Free-Float 35,7%
Chart EQT AB (PUBL)
Duration : Period :
EQT AB (publ) Technical Analysis Chart | EQT | SE0012853455 | MarketScreener
Technical analysis trends EQT AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 40,05 €
Average target price 44,90 €
Spread / Average Target 12,1%
EPS Revisions
Managers and Directors
Christian Otto Sinding Chief Executive Officer & Managing Partner
Kim Henriksson Chief Financial Officer
Yngve Conni Jonsson Director
Caspar Mats Andreas Callerstr÷m Chief Operating Officer & Deputy CEO
Edith W. Cooper Independent Director
Sector and Competitors